42 results
8-K
EX-99.1
NKTX
Nkarta Inc
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
diseases as well as its ability to enable long-term remissions via a “reset” of the immune system through the elimination of pathogenic B cells. All … , such as long-term use of immunosuppressants like glucocorticoids. It is estimated that approximately 140,000 people in the U.S. are living with vasculitis
8-K
EX-1.1
NKTX
Nkarta Inc
28 Mar 24
Other Events
4:08pm
described in, the Registration Statement, the General Disclosure Package and the Prospectus) or long-term debt of the Company, or any dividend … any change in the capital stock or long-term debt of the Company, or any change, or any development involving a prospective change, in or affecting
424B5
ik5z2gra
25 Mar 24
Prospectus supplement for primary offering
8:15pm
8-K
EX-99.1
f6k1ggf8 zdqm
25 Mar 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
yy3nxrpt
8 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-99.1
bynodo
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
8-K
EX-99.2
c3bu4 o1ncgrnypz
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
PRE 14A
ebonib g44gm2
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-1.1
o1iw0sg30bgdav7 k0ii
28 Apr 22
Other Events
4:20pm